BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Travere Therapeutics Licenses Sparsentan to Renalys Pharma for Japan, South Korea, Taiwan, and Southeast Asia

Travere Therapeutics,announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin ...

January 29, 2024 | News

Eisai Seeks Approval in Japan for Ultrahigh-Dose Mecobalamin in ALS

This application is based on the results of JETALS (The Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS), a Phase III trial to evaluate e...

January 29, 2024 | News

Ascletis Initiates Phase III Trial of ASC40 (Denifanstat) for Acne Treatment with First Patient Dosed

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and e...

January 25, 2024 | News

Onward Therapeutics Initiates Phase 1 Trial for Bispecific Antibody OT-A201 Targeting Dual Immune Checkpoints

The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoral activity of OT-A201. The study is a Eur...

January 25, 2024 | News

EMA grants Orphan Drug Designation to GC Biopharma's Sanfilippo Syndrome (Type A) Treatment

GC1130A has previously achieved notable milestones by securing both Rare Pediatric Disease designation (RPDD) and Orphan Drug Designation (ODD) from the U....

January 24, 2024 | News

Australia's Island Pharma Advances ISLA-101 Study: Third Cohort Successfully Dosed

This achievement follows the recent confirmation from the Data Safety Review Committee that ISLA-101 has been deemed safe and well-tolerated in the 16 subj...

January 23, 2024 | News

AIM ImmunoTech Initiates Phase 1b/2 Trial for Ampligen® and AstraZeneca's Imfinzi® in Late-Stage Pancreatic Cancer

AIM ImmunoTech Inc. announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM&rs...

January 23, 2024 | News

Vaxart Gets $9.27M BARDA Award for Phase 2b COVID-19 Oral Pill Study

“We are very honored to receive this BARDA award, which will support the innovative approach of our oral pill vaccine platform,” said Dr. Micha...

January 22, 2024 | News

AstraZeneca's IMFINZI Combo Shows Significantly Improved Survival in Liver Cancer

Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with TACE and bevacizumab demo...

January 22, 2024 | News

InnoCare Prescribes Tafasitamab Combo for Diffuse Large B-Cell Lymphoma in Greater Bay Area's Early Access Program

The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been appr...

January 22, 2024 | News

Molecule AI Spearheads Pharmaceutical Transformation with AI-Driven Drug Discovery Innovations

Molecule AI, on a mission to accelerate drug discovery through the innovative use of artificial intelligence, is making significant...

January 20, 2024 | News

Eisai's Fycompa Injection Approved in Japan, Paving the Way for Non-Oral Antiepileptic Treatment

Fycompa is a first-in-class AED discovered at Eisai’s Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor an...

January 20, 2024 | News

Sanyou Introduces Super Trillion Peptide Molecule Discovery Platform

The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral part of the "Sanyou Super Trillion Innovative Biopharmaceutical Discovery Plat...

January 20, 2024 | News

Kindeva Drug Delivery Acquires Summit Biosciences, a Nasal Drug Development Specialist

The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, further expanding Kindeva&rs...

January 19, 2024 | News

Stay Connected